Investment Rating - The report assigns a "Buy" rating for the company, indicating a potential upside in the stock price [6][12]. Core Insights - The company has achieved global sales exceeding 400 million units, with the "THE MONSTERS" series alone accounting for over 100 million units sold [7]. - The company is expected to experience significant revenue growth in 2025, with projected revenues between RMB 35.6 billion and RMB 43.6 billion, representing a year-on-year increase of 173% to 234% [12]. - New product launches in late 2025 and early 2026 have generated positive market responses, with some products showing a premium of approximately 48% [12]. - The company is strengthening its long-term development foundation by expanding its membership base to over 100 million and increasing its global store count to over 700 [12]. - The company is exploring new business avenues, including jewelry, desserts, theme parks, clothing, and film [12]. - Profit forecasts for 2025 to 2027 are optimistic, with expected net profits of RMB 12.26 billion, RMB 17.8 billion, and RMB 24.6 billion, respectively, indicating substantial growth rates [12]. Financial Summary - The company reported a net profit of RMB 476 million in 2022, with projections of RMB 1.08 billion in 2023 and RMB 3.13 billion in 2024, reflecting a significant recovery and growth trajectory [10]. - Earnings per share (EPS) are expected to rise from RMB 0.35 in 2022 to RMB 9.13 in 2025, showcasing a strong growth potential [10]. - The price-to-earnings (P/E) ratio is projected to decrease from 685 in 2022 to 26 in 2025, indicating an attractive valuation as earnings grow [10].

Investment Rating - The report assigns a "Buy" rating to the company, indicating a potential upside in the stock price [4][5]. Core Insights - The company is expected to achieve a revenue of RMB 429.7-466.7 billion in 2025, representing a year-on-year growth of 16%-26%. The net profit attributable to shareholders is projected to be RMB 49.7-54.0 billion, also reflecting a growth of 16%-26% [5][6]. - The company plans to list in Hong Kong to accelerate its global expansion, aiming to enhance its commercial credibility and brand influence, particularly in high-end markets in Europe [6]. - The company is transitioning from a hardware provider to a platform-based enterprise by expanding into AI industrial software, with net profit forecasts of RMB 52.5 billion, RMB 63.5 billion, and RMB 73.8 billion for 2025, 2026, and 2027 respectively [6]. Summary by Sections Company Overview - The company operates in the electrical equipment industry, with a current A-share price of RMB 75.45 and a target price of RMB 88 [1][4]. - The company has a market capitalization of RMB 180.97 billion and a total share count of approximately 2.71 billion [1]. Financial Performance - The company reported a projected revenue of RMB 113.0-150.1 billion for Q4 2025, with a year-on-year change ranging from a 3% decline to a 29% increase [5]. - The company’s revenue structure shows a significant contribution from the new energy vehicle and rail transportation sectors, accounting for 45.2% of the product mix [2]. Future Projections - The company anticipates a steady increase in net profit over the next three years, with expected growth rates of 22.5%, 21.1%, and 16.2% for 2025, 2026, and 2027 respectively [6][8]. - The projected earnings per share (EPS) for the same years are RMB 1.9, RMB 2.3, and RMB 2.7, with corresponding price-to-earnings (P/E) ratios of 39, 32, and 28 [6][8].

Investment Rating - The report assigns a "Buy" rating for the company, indicating a potential upside in the stock price [6][12]. Core Insights - The company has achieved global sales exceeding 400 million units, with the "THE MONSTERS" series alone accounting for over 100 million units sold [7]. - The company is expected to experience significant revenue growth in 2025, with projected revenues between RMB 35.6 billion and RMB 43.6 billion, representing a year-on-year increase of 173% to 234% [12]. - New product launches in late 2025 and early 2026 have generated positive market responses, with some products showing a premium of approximately 48% [12]. - The company is strengthening its long-term development foundation by expanding its membership base to over 100 million and increasing its global store count to over 700 [12]. - The company is exploring new business avenues, including jewelry, desserts, theme parks, clothing, and film [12]. - Profit forecasts for 2025 to 2027 are optimistic, with expected net profits of RMB 12.26 billion, RMB 17.8 billion, and RMB 24.6 billion, respectively, indicating substantial growth [12]. Financial Summary - The company reported a net profit of RMB 476 million in 2022, with projections of RMB 1.08 billion in 2023 and RMB 3.13 billion in 2024, reflecting a significant recovery and growth trajectory [10]. - Earnings per share (EPS) are expected to rise from RMB 0.35 in 2022 to RMB 9.13 in 2025, showcasing a strong growth rate [10]. - The price-to-earnings (P/E) ratio is projected to decrease from 685 in 2022 to 26 in 2025, indicating improved valuation as earnings grow [10].

Investment Rating - The report assigns a "Buy" rating to the company, indicating a potential upside in the stock price [4]. Core Insights - The company is expected to achieve a revenue of RMB 429.7-466.7 billion in 2025, representing a year-on-year growth of 16%-26%. The net profit attributable to shareholders is projected to be RMB 49.7-54.0 billion, also reflecting a growth of 16%-26% [5][6]. - The company plans to list in Hong Kong to accelerate its global expansion, aiming to enhance its commercial credibility and brand influence, particularly in high-end markets in Europe [6]. - The company is transitioning from a hardware provider to a platform-based enterprise by expanding into AI industrial software, with net profit forecasts of RMB 52.5 billion, RMB 63.5 billion, and RMB 73.8 billion for 2025, 2026, and 2027 respectively [6]. Financial Performance Summary - For 2025, the company anticipates a revenue range of RMB 429.7-466.7 billion, with a net profit of RMB 49.7-54.0 billion, and a non-GAAP net profit of RMB 47.6-51.7 billion [5]. - The company’s revenue is expected to grow significantly due to increased demand from downstream customers and strategic market opportunities in sectors like lithium batteries and semiconductors [6]. - The projected earnings per share (EPS) for 2025, 2026, and 2027 are RMB 1.9, RMB 2.3, and RMB 2.7 respectively, with corresponding price-to-earnings (P/E) ratios of 39, 32, and 28 [6][8].

Investment Rating - The report assigns a "Buy" rating for the company, indicating a potential upside of 15% to 35% [4][11]. Core Insights - The company is expected to significantly promote sodium batteries in commercial vehicles, passenger cars, battery swapping, and energy storage in 2026, which will help activate the incremental market for electric vehicles in cold regions [8]. - The company is projected to maintain its position as the global leader in battery shipments in 2025, with aggressive capacity expansion to meet strong demand [8]. - The company’s net profit is forecasted to be RMB 69.52 billion, RMB 90.79 billion, and RMB 112.01 billion for 2025, 2026, and 2027 respectively, with year-over-year growth rates of 37%, 31%, and 23% [10][12]. Company Overview - The company operates in the power equipment industry, with a current H-share price of HKD 511.00 as of February 10, 2026 [3]. - The company has a total issued share count of 4,563.85 million, with H-shares accounting for 155.92 million [3]. - The company’s major shareholder holds a 22.46% stake [3]. Financial Projections - The company’s projected net profits for 2025, 2026, and 2027 are RMB 69.52 billion, RMB 90.79 billion, and RMB 112.01 billion, respectively, with corresponding EPS of RMB 15.25, RMB 19.92, and RMB 24.57 [10][12]. - The H-share price-to-earnings (P/E) ratios for 2025, 2026, and 2027 are expected to be 29, 22, and 18 times, respectively [8][10]. Market Position - The company is expected to achieve a market share of 39.2% in power batteries and 30% in energy storage batteries by 2025, with year-over-year shipment growth rates of 35.7% and 80% respectively [8]. - The company is actively expanding its production capacity, with construction projects valued at RMB 37.366 billion underway, reflecting a 25.6% increase from the end of 2024 [8].

Investment Rating - The report assigns a "Buy" rating for the company, indicating a potential upside of 15% to 35% [4][11]. Core Insights - The company is expected to significantly promote sodium batteries in 2026 across commercial vehicles, passenger cars, battery swapping, and energy storage, which will help activate incremental market demand [8]. - The company is projected to maintain its position as the global leader in battery shipments in 2025, with aggressive capacity expansion to meet strong demand [8]. - The company’s net profit forecasts for 2025, 2026, and 2027 are RMB 695 billion, RMB 908 billion, and RMB 1,120 billion, respectively, with year-over-year growth rates of +37%, +31%, and +23% [8][10]. Company Overview - The company operates in the power equipment industry, with a current H-share price of HKD 511.00 and a market capitalization of 0 billion [3]. - The company has a total of 4,563.85 million shares issued, with major shareholders holding 22.46% [3]. Financial Performance - The company’s projected earnings per share (EPS) for 2025, 2026, and 2027 are RMB 15.3, RMB 19.9, and RMB 24.6, respectively [8][10]. - The price-to-earnings (P/E) ratios for 2025, 2026, and 2027 are expected to be 29, 22, and 18 times, respectively [8][10]. Market Demand and Capacity Expansion - The demand for lithium batteries is expected to continue growing, with the company’s market share in power and energy storage batteries projected to be 39.2% and 30%, respectively, in 2025 [8]. - The company is actively expanding its production capacity, with construction projects valued at RMB 373.66 billion underway, representing a 25.6% increase from the end of 2024 [8].

Investment Rating - The report assigns a "Buy" rating for the company, indicating a potential upside of 15% to less than 35% [2][4]. Core Insights - The company has entered into a global strategic collaboration with Eli Lilly to accelerate the global development of innovative drugs in oncology and immunology. The company will lead the research and development from drug discovery to clinical concept verification in China, retaining all rights in Greater China while Eli Lilly obtains exclusive rights outside this region [4][5]. - The company expects a revenue increase of 45% in 2025, projecting total product revenue of approximately RMB 11.9 billion, with Q4 alone expected to generate around RMB 3.3 billion, reflecting a year-over-year growth of over 60% [5]. - The company has a strong pipeline with 13 commercialized oncology products, and the collaboration with Eli Lilly is expected to enhance its research capabilities and market position [5]. Financial Summary - The company forecasts net profits of RMB 354 million in 2025, RMB 1.427 billion in 2026, and RMB 2.404 billion in 2027, with significant year-over-year growth rates of 304% and 68.4% for 2026 and 2027, respectively [7][9]. - Earnings per share (EPS) are projected to be RMB 0.20 in 2025, RMB 0.82 in 2026, and RMB 1.39 in 2027, with corresponding price-to-earnings (P/E) ratios of 346X, 86X, and 51X [7][9]. - The total revenue is expected to grow from RMB 6.206 billion in 2023 to RMB 20.063 billion by 2027, indicating a robust growth trajectory [9].

Investment Rating - The report assigns a "Buy" rating for the company, indicating a potential upside of 15% to less than 35% [2][4]. Core Insights - The company has entered into a global strategic collaboration with Eli Lilly to accelerate the global development of innovative drugs in oncology and immunology. The company will lead the research from drug discovery to clinical concept verification in China, while Eli Lilly will have exclusive rights outside Greater China [4][5]. - The company is expected to achieve a revenue increase of 45% in 2025, with projected total product revenue of approximately RMB 11.9 billion. The fourth quarter alone is anticipated to generate around RMB 3.3 billion, reflecting a year-over-year growth of over 60% [5]. - The company has a strong pipeline with 13 commercialized oncology products, and the collaboration with Eli Lilly is expected to enhance its research capabilities and market position [5]. Financial Summary - The company is projected to achieve net profits of RMB 354 million in 2025, RMB 1.427 billion in 2026, and RMB 2.404 billion in 2027, reflecting significant year-over-year growth of 304% and 68.4% respectively [7][9]. - Earnings per share (EPS) are expected to be RMB 0.20 in 2025, RMB 0.82 in 2026, and RMB 1.39 in 2027, with corresponding price-to-earnings (P/E) ratios of 346X, 86X, and 51X [7][9]. - The total revenue is forecasted to grow from RMB 6.206 billion in 2023 to RMB 20.063 billion in 2027, indicating a robust growth trajectory [9].

2026 年 02 月 06 日 | C0062@capital.com.tw | | | --- | --- | | 王睿哲 目标价(港元) | 26.5 | 公司基本资讯 | 产业别 | | 医药生物 | | --- | --- | --- | | H 股价(2026/2/5) | | 20.52 | | 恒生指数(2026/2/5) | | 26,885.24 | | 股价 12 个月高/低 | | 28.80/12.61 | | 总发行股数(百万) | | 2,670.43 | | H 股数(百万) | | 540.97 | | H 市值(亿港元) | | 111.01 | | | | 上海复星高科技 | | 主要股东 | | (集团)有限公司 | | | | (36.15%) | | 每股净值(元) | | 18.06 | | 股价/帐面净值 | | 1.14 | | | 一个月 | 三个月 一年 | | 股价涨跌(%) | -0.97% | -9.92% 62.68% | 近期评等 | 出刊日期 | 前日收盘 | 评等 | | --- | --- | --- | | 2025/12/10 | 21 ...

Investment Rating - The report assigns a "Buy" rating for Fosun Pharma (02196.HK) with a target price of HKD 26.5, indicating a potential upside from the current price of HKD 20.52 [1][6]. Core Insights - Fosun Pharma's subsidiary, Fosun Hani, has granted Eisai the rights to develop, manufacture, and commercialize the PD-1 monoclonal antibody, Surulitinib, in Japan, with potential upfront payments and sales milestones totaling up to USD 39 million [7]. - Surulitinib has shown strong competitive advantages, having been launched in China in March 2022 and covering multiple indications. The revenue for Surulitinib is projected to reach RMB 1.31 billion in 2024, reflecting a year-on-year growth of 17.2% [8]. - The company is actively expanding into new markets and indications, with ongoing clinical trials and regulatory submissions for various cancers, which are expected to drive future growth [8]. - Profit forecasts for Fosun Pharma indicate net profits of RMB 3.32 billion, RMB 4.68 billion, and RMB 4.77 billion for 2025, 2026, and 2027 respectively, with year-on-year growth rates of 19.9%, 40.8%, and 2.1% [8]. Financial Summary - The company is expected to achieve net profits of RMB 3.32 billion in 2025, RMB 4.68 billion in 2026, and RMB 4.77 billion in 2027, with corresponding earnings per share (EPS) of RMB 1.24, RMB 1.75, and RMB 1.79 [9]. - The projected price-to-earnings (P/E) ratios for H shares are 15X for 2025, 11X for 2026, and 11X for 2027, indicating a relatively low valuation compared to growth prospects [8][9]. - Revenue forecasts show an increase from RMB 44.87 billion in 2025 to RMB 49.88 billion in 2026, and further to RMB 53.41 billion in 2027 [11].